This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
February 20, 2018
GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology
February 20, 2018
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast
February 19, 2018
SAVE THE DATE: Wilson Therapeutics to Host Capital Markets Day in Stockholm on 21 March 2018
February 16, 2018
Notice of Nexstim Plc 2017 Full Year Results
February 16, 2018
First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
February 15, 2018
MIPS – YEAR-END REPORT 2017
February 15, 2018
Targovax ASA: Fourth quarter and full year 2017 results
February 14, 2018
Pulmonx’ endobronchial valve technology explained by American Journal of Respiratory and Critical Care Medicine
February 14, 2018
Wilson Therapeutics to host conference call to provide fourth quarter 2017 business update
February 07, 2018
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma